Table 1.
Summary, Patient Characteristics and Outcomes
| Characteristic/Outcome | N (%) or Median (Range) |
|---|---|
| Patient Gender | |
| Male | 20 (74) |
| Female | 7 (26) |
| Age at Transplant (Years) | 50 (19 – 68) |
| Histology | |
| CTCL | 11 (41) |
| Other | 16 (59) |
| Donor Type | |
| Sibling | 15(56%) |
| Matched Unelated Donor | 12 (44) |
| Disease Status at Transplant | |
| 1st CR/ 2nd CR/ PR | 10 (37) |
| Relapse/ Progression/ Induction Failure | 17 (63) |
| Chemotherapy responsiveness | |
| Refractory | 11 (41) |
| Sensitive | 16 (59) |
| Stem Cell Source | |
| Bone Marrow | 3 (11) |
| Peripheral Blood | 24 (89) |
| Total Regimens Prior to HCT | 4 (1 – 9) |
| CTCL | 6 (4 – 9) |
| Other | 3 (1 – 8) |
| GVHD Prophylaxis | |
| CSA/MMF-Based | 9 (33) |
| Sirolimus-Based | 18 (67) |
| Engraftment: Days to ANC > 500 | 14 (12 – 23) |
| Acute GVHD (yes) | 13 (48) |
| Grade I | 4 |
| Grade II | 5 |
| Grade III | 0 |
| Grade IV | 4 |
| None | 14 (52) |
| Chronic GVHD | 18 (67) |
| Limited | 3 |
| Extensive | 15 |
| None | 3 (11) |
| Not Evaluable (expired<100 days) | 6 (22) |
| Relapse/Progression Post-HCT | 8 (30) |
| Cause of Death | |
| Disease Progression | 5 |
| Infection/GVHD | 9 |
| Day 100 Mortality | |
| Disease Progression | 1 |
| Infection/GVHD | 5 |
| Follow-up (Months) | |
| All patients | 15.6 (1.0 – 104.0) |
| Alive | 35.7 (12.6 – 103.3) |
| Dead | 6.0 (1.9 – 12.2) |
CTCL = cutaneous T-cell lymphoma, CR = complete remission, PR = partial remission, GVHD = graft vs host disease, CSA = cyclosporine A, MMF = mycophen-olate mofetil,,